At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
DHA Omega-3 +1 moredrug
Likely dose
DHA Omega-3 1,200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Docosahexaenoic Acid Augmentation of Cortical Attention Networks in ADHD
In Brief
A Phase 3 clinical trial evaluating DHA Omega-3 and Placebo for Attention Deficit Disorder. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The study hypothesis is that DHA is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with ADHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Disorder
CountriesUnited States
Collaboratorsdsm-firmenich Switzerland AG
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartSep 2013
Primary CompletionMar 2017
TodayJul 2026
First PostedJun 21, 2013
Enrollment StartSep 1, 2013
Primary CompletionMar 3, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.0 years ago
Interventions
DHA Omega-3drug
Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
Placebodrug
corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)